Phaseline

Companies › argenx

argenx: clinical trials, targets and expected readouts

7 active drug programs in 38 registered trials: 18 Phase 2, 11 Phase 3, 6 Phase 1, 3 Phase 4; Other, Neurology, Immunology, Hematology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Efgartigimod Alfa (PH20)
IgG receptor FcRn large subunit p51 antagonist
FCGRTPhase 4New Onset Generalized Myasthenia Gravis (gMG); Primary Sjogrens Disease; Primary Immune Thrombocytopenia; Myasthenia Gravis, Ocular …Mar 2027
Empasiprubart
FcRn antagonist
FCRN, FCRL5Phase 3Chronic Inflammatory Demyelinating Polyneuropathy; Multifocal Motor Neuropathy (MMN); Dermatomyositis; AChR-Ab Seropositive Generalized Myasthenia Gravis …Nov 2026
ARGX-119
DOK7-targeted therapy for congenital myasthenic syndrome
–Phase 2Spinal Muscular Atrophy (SMA); Congenital Myasthenic SyndromeAug 2027
ARGX-117
FcγRIIB agonist / IgG4-Fc fusion protein
FCGR2BPhase 2Multifocal Motor Neuropathy (MMN); Delayed Graft FunctionSep 2029
ARGX-121
IgA immune complex inhibitor; blocks FcαRI signaling pathway
FCARPhase 2Immunoglobulin A Nephropathy (IgAN)Oct 2029
Adimanebart–Phase 1Healthy Volunteers (HV)Dec 2026
ARGX-124–Phase 1Healthy VolunteersDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07782775Efgartigimod Alfa (PH20)Phase 1Healthy VolunteerOtherSep 2026
NCT06284954EmpasiprubartPhase 2DermatomyositisImmunologyNov 2026
NCT07673601AdimanebartPhase 1Healthy Volunteers (HV)OtherDec 2026
NCT06860633Efgartigimod Alfa (PH20)Phase 4Myasthenia Gravis CrisisNeurologyDec 2026
NCT07377396ARGX-124Phase 1Healthy VolunteersOtherDec 2026
NCT06765161Efgartigimod Alfa (PH20)Phase 3Myasthaenia GravisNeurologyJan 2027
NCT04833894Efgartigimod Alfa (PH20)Phase 2Generalized Myasthenia GravisNeurologyMar 2027
NCT06655155Efgartigimod Alfa (PH20)Phase 2Systemic Sclerosis (SSc)ImmunologyMar 2027
NCT07612020EmpasiprubartPhase 1Healthy VolunteersOtherMar 2027
NCT04280718Efgartigimod Alfa (PH20)Phase 2Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)NeurologyApr 2027
NCT06909214Efgartigimod Alfa (PH20)Phase 4New Onset Generalized Myasthenia Gravis (gMG)NeurologyMay 2027
NCT06453694Efgartigimod Alfa (PH20)Phase 2Optic NeuritisNeurologyJun 2027
NCT06684847Efgartigimod Alfa (PH20)Phase 3Primary Sjogrens DiseaseImmunologyJul 2027
NCT06436742ARGX-119Phase 1Congenital Myasthenic SyndromeNeurologyAug 2027
NCT06392386Efgartigimod Alfa (PH20)Phase 2Generalized Myasthenia GravisNeurologySep 2027
NCT06920004EmpasiprubartPhase 3Chronic Inflammatory Demyelinating PolyneuropathyNeurologySep 2027
NCT07072988Efgartigimod Alfa (PH20)Phase 4Myasthenia Gravis, GeneralizedNeurologyOct 2027
NCT07091630EmpasiprubartPhase 3Chronic Inflammatory Demyelinating PolyneuropathyNeurologyOct 2027
NCT04812925Efgartigimod Alfa (PH20)Phase 3Primary Immune ThrombocytopeniaHematologyOct 2027
NCT07673627EmpasiprubartPhase 2AChR-Ab Seropositive Generalized Myasthenia GravisNeurologyOct 2027
NCT06503731Efgartigimod Alfa (PH20)Phase 2Antibody-mediated RejectionOtherNov 2027
NCT06558279Efgartigimod Alfa (PH20)Phase 3Myasthenia Gravis, OcularNeurologyDec 2027
NCT07822776Efgartigimod Alfa (PH20)Phase 2Encephalitis AutoimmuneImmunologyDec 2027
NCT07610564EmpasiprubartPhase 1Multifocal Motor Neuropathy (MMN)NeurologyFeb 2028
NCT07025330Efgartigimod Alfa (PH20)Phase 2IgG4-related DiseaseOtherMar 2028
NCT07284420Efgartigimod Alfa (PH20)Phase 2AChR-Ab Seropositive Generalized Myasthenia GravisNeurologyMar 2028
NCT07284420EmpasiprubartPhase 2AChR-Ab Seropositive Generalized Myasthenia GravisNeurologyMar 2028
NCT06831058Efgartigimod Alfa (PH20)Phase 2Immune-mediated Thrombotic Thrombocytopenic PurpuraHematologyMay 2028
NCT07570316Efgartigimod Alfa (PH20)Phase 3Graves' DiseaseMetabolic and endocrineJun 2028
NCT07596849Efgartigimod Alfa (PH20)Phase 3Graves DiseaseMetabolic and endocrineJun 2028
NCT06544499Efgartigimod Alfa (PH20)Phase 3Primary Immune Thrombocytopenia (ITP)HematologyJun 2028
NCT06298552Efgartigimod Alfa (PH20)Phase 3Generalized Myasthenia GravisNeurologyJun 2028
NCT07194850Efgartigimod Alfa (PH20)Phase 2Immune Thrombocytopenia (ITP)HematologyOct 2028
NCT07287982ARGX-119Phase 2Spinal Muscular Atrophy (SMA)NeurologyMay 2029
NCT05405361ARGX-117Phase 2Multifocal Motor Neuropathy (MMN)NeurologySep 2029
NCT07773727ARGX-121Phase 2Immunoglobulin A Nephropathy (IgAN)GenitourinaryOct 2029
NCT06742190EmpasiprubartPhase 3Multifocal Motor Neuropathy (MMN)NeurologyDec 2029
NCT05907096ARGX-117Phase 2Delayed Graft FunctionOtherMay 2030

Targets

FCGR2B (1) FCGRT (1) FCRN (1) FCRL5 (1) FCAR (1)

Companies with the same targets

Nuvig Therapeutics Zenas BioPharma (USA) BioInvent International Johnson & Johnson (Janssen) Sanofi UCB Biopharma SRL Immunovant Sciences

Companies built like this

Pharmazz Keymed Biosciences Co.Ltd Chongqing Claruvis Pharmaceutical Harmony Biosciences Management Merz Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.